First results from any randomized, controlled COVID-19 vaccine booster trial demonstrate a relative vaccine efficacy of 95.6% against disease during a period when Delta was the prevalent strainIn trial with more than 10,000 participants 16 years of age and older, COVID-19 booster was found to have a favorable safety profileCompanies plan to submit these data to FDA, EMA and other regulatory agenci